| Name | Roquefort Therapeutics |
|---|---|
| Epic | ROQ |
| Isin | GB00BMDQ2T15 |
| Industry | Open End and Miscellaneous Investment Vehicles |
| Latest share price | 4.05p | Net gearing | n/a |
|---|---|---|---|
| Market capitalisation | £5.50 | Debt ratio | n/a |
| Shares in issue | 135.74 | Debt-to-equity ratio | n/a |
| P/E ratio | n/a | Assets / equity ratio | n/a |
| Total dividends per share | n/a | Price to book value | n/a |
| Dividend yield | n/a | ROCE | n/a |
| Dividend cover | n/a | EPS growth | n/a |
| Earning per share | -1.35 | 52-week high / low | 3.35p / 9.25p |
| Type | Ex-date | Pay-date | Net-dividend |
|---|---|---|---|
| No dividends declared | |||
| Company name | Roquefort Therapeutics |
|---|---|
| Address | Eccleston Yards, 25 Eccleston Place, London, United Kingdom, SW1W 9NF |
| Telephone | +44 (0)20 3290 9339 |
| Website | http://www.roquefortinvest.com/ |
| Director | Position |
|---|---|
| Dr Simon Sinclair | Non-Executive Director |
| Mr Dr Darrin Disley | Non-Executive Director |
| Ms Jean Duvall | Non-Executive Director |
| Mr Stephen Paul West | Executive Chairman |
| Mr Trevor Ajanthan (Ajan) Reginald | Chief Executive Officer |
| Dr Michael Stein | Independent Non-Executive Director |
| Mr Professor Sir Martin Evans | Chief Scientific Officer |
| Assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Reporting date | 31/12/23 | 31/12/22 | 31/12/21 |
| Intangible asssets and goodwill | 5.34 | 5.34 | 1.48 |
| Investments and other non-current assets | n/a | n/a | n/a |
| Total non-current assets | 5.39 | 5.34 | 1.48 |
| Inventory / work in progress | n/a | n/a | n/a |
| Trade and other receivables | 0.16 | 0.1 | 2.18 |
| Cash and equivalents | 0.54 | 2.32 | 0.9 |
| Other current assets and asset held for resale | n/a | n/a | n/a |
| Total of all assets | 6.09 | 7.77 | 4.56 |
| Liabilities £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Short term liabilities | 0.31 | 0.28 | 0.2 |
| Long term liabilities | 0.28 | 0.28 | 0.28 |
| Other liabilites / pension etc | n/a | n/a | n/a |
| Total of all liabilities | 0.59 | 0.56 | 0.48 |
| Net assets £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Net assets | 5.5 | 7.21 | 4.08 |
| Equity £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Share capital | 1.29 | 1.29 | 0.72 |
| Minority interests | n/a | n/a | n/a |
| Retained earnings | -4.29 | -2.55 | -0.91 |
| Share premium account | 4.4 | 4.4 | 3.46 |
| Total equity | 5.5 | 7.21 | 4.08 |
| Income £ (m) | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | n/a | n/a | n/a |
| Operating profit | -1.93 | -1.63 | -0.92 |
| Pre-tax profit | -1.93 | -1.63 | -0.92 |